only support oncology providers to
develop and implement Treatment
Plan and Summary Programs within
their practices, but will provide us with
the unique opportunity of studying the
benefits and burdens of the process
for both patients and practices.
Group and Principal Investigator for the evaluation study
CLINICAL OPINION
(PCO) in January 2009. PCOs are intended
to offer timely preliminary clinical direction
to oncologists following the publication or
presentation of potentially practice-changing
data from major studies.
to Predict Response to Anti-Epidermal Growth
Factor Receptor Monoclonal Antibody Therapy," addresses
the importance of KRAS gene mutation testing in patients
with metastatic colorectal carcinoma to predict response to
anti-epidermal growth factor receptor (anti-EGFR) monoclo-
nal antibody (MoAb) therapy with cetuximab or panitumum-
ab. www.asco.org/pco/kras
Oncology 2009 Clinical Evidence Review on Radiofrequency
Ablation of Hepatic Metastases From Colorectal Cancer."
Clinical evidence reviews are a systematic review of existing
literature on topics of interest to the oncology community.
These reviews address areas associated with clinical uncer-
tainty and likely practice variation, but for which there are
insufficient data to inform practice recommendations.
www.asco.org/guidelines/cer/rfa
funded by Susan G. Komen for the Cure
data in a registry that can be used for practice-based quality improve-
ment activities and national quality monitoring for breast cancer care.
seen by the ASCO Registry Steering Group. Using a web-based applica-
tion, participating oncologists and their staff enter clinical data about
every newly diagnosed patient with stage 0 through stage III breast
cancer into the Registry. They then generate and discuss the treatment
plans and summaries with all of their patients during the pilot period.